floriparesort.com – 23 June 2026 | AbbVie to buy Apogee [titlebase] in a massive $10.9 billion deal, marking a significant expansion of its immunology portfolio. The acquisition is expected to close in the third quarter of 2026, subject to regulatory approvals. Apogee Therapeutics, a biotech company, has been developing innovative treatments for inflammatory and immunological diseases. The deal gives AbbVie access to a pipeline of clinical-stage assets, including a late-stage monoclonal antibody targeting IL-13 in atopic dermatitis.
The announcement comes at a time when the US stock market is experiencing a mixed day of trading, with the S&P 500 slipping 0.4% and the Dow Jones Industrial Average adding 148 points. The oil market is also experiencing a decline in prices, following talks between the US and Iran over the weekend. The price of Brent crude oil fell 3.2% to $77.52, while benchmark US crude oil fell 2.6% to $73.86 per barrel.
AbbVie to buy Apogee [titlebase] is a strategic move to strengthen its position in the immunology market. The company’s shares have moved 4.79% on the market, and are now trading at a price of $226.8625. The acquisition is expected to add to earnings beginning in 2032. Apogee’s pipeline includes an experimental drug for moderate to severe atopic dermatitis, which will complement AbbVie’s existing portfolio of immunology treatments.
The deal is a significant milestone for AbbVie, as it continues to expand its portfolio of innovative treatments. AbbVie to buy Apogee [titlebase] demonstrates the company’s commitment to investing in cutting-edge research and development. The acquisition is expected to drive growth and increase shareholder value in the long term.
![1st Death in NYC Outbreak [titlebase]: A Critical Moment in the Cyclosporiasis Crisis](https://www.floriparesort.com/wp-content/uploads/2026/07/1st-death-in-nyc-outbreak-titlebase-a-critical-moment-in-the-cyclosporiasis-crisis-60x60.webp)
In related news, Chevron has struck a power deal with Microsoft for a West Texas AI data center. The 2.7-gigawatt project will have its own on-site power plant fueled by Chevron’s local natural-gas production. Meanwhile, Morgan Stanley is weighing an expansion to Dallas with a $1.33 billion office-building deal.
AbbVie to buy Apogee [titlebase] is a testament to the company’s vision to become a leader in the immunology market. The acquisition is expected to bring significant benefits to patients, shareholders, and the company as a whole. As the US stock market continues to experience fluctuations, AbbVie’s strategic move is expected to drive growth and stability in the long term.
![GSK to buy Nuvalent for $10.6B [titlebase] in a Historic Deal, Expanding its Oncology Portfolio](https://www.floriparesort.com/wp-content/uploads/2026/06/gsk-to-buy-nuvalent-for-10-6b-titlebase-in-a-historic-deal-expanding-its-oncology-portfolio-60x60.webp)
In conclusion, AbbVie to buy Apogee [titlebase] is a significant development in the pharmaceutical industry. The acquisition is expected to expand AbbVie’s immunology portfolio, drive growth, and increase shareholder value. As the company continues to invest in innovative research and development, it is poised to become a leader in the immunology market.